By studying G protein–coupled receptor (GPCR) signaling in a range of uveal melanoma cell lines, Jenna Aumiller and colleagues have discovered a way to make these cells more sensitive to compounds that inhibit cancer-linked (or oncogenic) signaling pathways.
